References
- Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202-209. https://doi.org/10.1016/j.jhep.2020.03.039
- Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312
- Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14:889-919. https://doi.org/10.1007/s12072-020-10094-2
- Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78:1966-1986. https://doi.org/10.1097/HEP.0000000000000520
- Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-1556. https://doi.org/10.1016/j.jhep.2023.06.003
- Kim GA, Moon JH, Kim W. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity. Clin Mol Hepatol 2023;29:831-843. https://doi.org/10.3350/cmh.2023.0277
- Yoon EL, Jun DW. Waiting for the changes after the adoption of steatotic liver disease. Clin Mol Hepatol 2023;29:844-850. https://doi.org/10.3350/cmh.2023.0291
- Kang SH, Lee HW, Yoo JJ, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. https://doi.org/10.3350/cmh.2021.0178
- Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol 2023;29 Suppl 4:S17-S31. https://doi.org/10.3350/cmh.2022.0367
- Cho JY, Sohn W. The growing burden of non-alcoholic fatty liver disease on mortality. Clin Mol Hepatol 2023;29:374-376. https://doi.org/10.3350/cmh.2023.0084